Gracell Biotechnologies Inc 's ROA from the fourth quarter of 2022 to the fourth quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Gracell Biotechnologies Inc 's ROA in the fourth quarter of 2022?
Gracell Biotechnologies Inc recorded a cumulative net loss of $-88 million during 12 months ending in the fourth quarter of 2022, resulting in a negative return on assets (ROA) of -33.24%.

However, within the Healthcare sector 635 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2022 from to 5140.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2022) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2021) IV. Quarter
Y / Y Total Assets Change	-10.71 %	-13.24 %	-25.72 %	-11.02 %	-25.72 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-88	-71	-71	-71	-71
Return On Assets (TTM)	-33.24 %	-26.12 %	-25.01 %	-23.3 %	-22.63 %
GRCL's Total Ranking	# 5140	#	#	#	# 4690
Total Assets (TTM) in million	214	318	240	288	240
Seq. Total Assets Change	-32.5 %	32.27 %	-16.52 %	19.78 %	-34.41 %
Seq. Net Income Change	-	-	-	-	-

GRCL's 5 Years Annual ROA >> Back to GRCL Management Effectiveness >> Compare GRCL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 257
Sector	# 636
Overall	# 4985

Return On Assets Statistics
High	Average	Low
-21.93 %	-29.3 %	-36.68 %
(Dec 31 2021)		(Dec 31 2022)

Financial Statements
Gracell Biotechnologies Inc 's Assets	$ 214 million	GRCL's Balance sheet
Gracell Biotechnologies Inc 's Income	$ -88 million	Quarterly GRCL's Income Statement
GRCL's Income by Division		See GRCL's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	FY	FY
Y / Y Total Assets Change	-12.9 %	124.77 %	-	-	-
Total Assets in million	316	363	162	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-88	-71	-32	0	0
Annual Return On Assets	-27.85 %	-19.53 %	-20.1 %	-	-

GRCL's 5 Years Annual ROA >> Back to GRCL Management Effectiveness >> Compare GRCL ROA to its Competitors

More Return On Assets Ratios
GRCL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GRCL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GRCL's Competitors
Subscribers only: Roa for Gracell Biotechnologies Inc 's Suppliers
Subscribers only: Return On Assets for GRCL's Customers

You may also want to know
GRCL's Roi	GRCL's Inventory Turnover Ratio	GRCL's Growth Rates	GRCL's Dividend Comparisons
	GRCL's Profitability Ratios	GRCL's Asset Turnover Ratio	GRCL's Dividend Growth
GRCL's Roe	GRCL's Valuation Ratios	GRCL's Financial Strength Ratios	GRCL's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2022, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:10:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.